We have localized the binding region of a previously described monoclonal anti-factor VIII (FVIII) inhibitory antibody (C5) to amino acid residues Thr351-Ser '5 of the thrombin-generated 54-kD fragment of the heavy chain of FVIII. Synthetic FVIII peptides were examined for the ability to competitively inhibit the binding of C5 to FVIII in an ELISA system. The synthetic FV1lI peptide Thr35'-Ser36-blocked C5 binding to FVIII in a dose-dependent manner in this system. Two other synthetic FVIII peptides, Asn340-Glu354 and Glu342-Asp3s' which partially overlapped Thr351-Ser*-5, also blocked C5 binding to FVIJI. Blocking of C5 binding with these peptides, however, required much greater concentrations (> 100 times stronger) than that required for Thr351-Ser365. The Thr3SI1Serm5 peptide also neutralized the FVIII inhibitory activity of C5 in plasma. A human FVIII inhibitor (anti-FVIII heavy chain alloantibody) was also partially neutralized by Thr351-Ser365. lies between a thrombin cleavage site (Arg372) and an activated protein C cleavage site (ArgA36) and may be at or near a region of functional importance in the expression of FVIII procoagulant activity.
Introduction
Factor VIII (FVIII)' circulates in plasma with von Willebrand factor as a noncovalently linked protein complex and plays an important role in the intrinsic pathway of coagulation. Activated FVIII functions as a nonenzymatic cofactor to accelerate the activation of factor X by factor IXa in the presence of calcium ions and phospholipid (1, 2) . The production of a FVIII molecule that lacks procoagulant activity, or the total lack of production of FVIII, results in hemophilia A, a Xlinked recessive bleeding disorder with a frequency ofapproximately 1 per 10,000 in the general population (3) .
The mature FVIII molecule is a single chain protein of 2,332 amino acid residues with a calculated molecular mass of 264,763 daltons (4) . FVIII purified from plasma by means of immunoaffinity chromatography consists of heterodimers of an 80-kD2 light chain in association with a heavy chain-containing species of 92-210 kD (5) (6) (7) (8) (9) (10) . The two chains are presumed to be associated via a calcium linkage (7, (9) (10) (11) (12) .
Thrombin digestion of the 80-kD light chain results in cleavage at Arg'689 to form a carboxyl-terminal 72-kD peptide (4, (6) (7) (8) 13) . Thrombin digestion of the 92-2 10-kD polypeptides results in cleavage at Arg74 with formation of the 92-kD amino-terminal heavy chain (14) and subsequently cleavage at Arg372 with formation of a 54-kD amino-terminal subunit and a 44-kD carboxyl-terminal subunit (4, (6) (7) (8) 13) . Further thrombin digestion cleaves the 54-kD peptide into a 30-and a 20-kD peptide (4) .
Inactivation of FVIII by activated protein C has been demonstrated to occur by cleavage of the 92-kD peptide, or its 54-kD thrombin cleavage fragment, at the proposed cleavage site Arg336, with generation ofa 45-kD fragment (7, 15) . Factor Xa inactivates FVIII by the same cleavage as activated protein C as well as by cleavage of the 72-kD peptide at Arg'72' with generation of a 67-kD peptide (7) .
The production of recombinant cDNA FVIII molecules with site-specific deletions and substitutions has helped identify critical thrombin cleavage sites necessary for activation of FVIII. These studies have shown that modification or deletion of the thrombin cleavage sites at Arg372 or Arg'689 result in loss of, or marked reduction of, FVIII cofactor activity (16) (17) (18) . It has also been demonstrated that alteration in the proposed activated protein C and factor Xa cleavage site at Arg336 results in a FVIII molecule with higher specific activity than normal, possibly due to resistance to proteolytic inactivation (16 (4, (6) (7) (8) 10 ; see also references 15, 36, and 37) . For the purpose of discussion in this paper, the molecular FVIII molecule, indicating the heterogeneous nature of the epitopes of these antibodies (6, 8, (21) (22) (23) (24) (25) .
In the studies reported here, synthetic FVIII peptides have been used to localize the binding regions of a FVIII-inhibiting monoclonal antibody (C5), and a human FVIII inhibitor alloantibody to the same 15-amino acid segment of the heavy chain of FVIII. This region is located between two important thrombin (Arg372) and activated protein C (Arg336) proteolytic cleavage sites and is likely to be at, or near, one or more sites of functional importance to the FVIII molecule.
Methods
Purification ofFVIII. The purification of FVIII from commercial factor VIII concentrates (Armour Pharmaceutical Co., Kankakee, IL) by immunoadsorbent chromatography has previously been described (5, 6, 13) . FVIII preparations prepared by this method had specific activities of 2,900-3,800 U/mg.
Monoclonal antibodies. Murine monoclonal anti-human FVIII antibodies were produced, purified, and characterized as described (6) .
Coagulation assays. Inhibition of FVIII activity by FVIII antibodies was measured in Bethesda units by a modification of the method of Kasper et al. (26) as previously described (6) . FVIII procoagulant activity was determined by an activated partial thromboplastin time (APTT) assay as previously described (5) Blocking ofhuman FVIII inhibitor alloantibody by synthetic FVIII peptides. Synthetic FVIII peptide was incubated at a final concentration of 0-5 mM with FVIII inhibitor plasma diluted 1:9 with barbitalbuffered saline and assayed as described above. The FVIII inhibitory activity of the inhibitor plasma diluted 1:9 was equivalent to an undiluted inhibitor plasma of4.7 Bethesda units. Further studies were done with partially purified inhibitor prepared as follows: 3.9 ml of FVIII inhibitor plasma was centrifuged and treated with 10 MM p-amidinophenylmethanesulfonyl fluoride (Chemicon, El Segundo, CA). The plasma was applied to a 1.0 X 11-cm protein A column. After washing the column with phosphate-buffered saline (0.02 M P04, 0. 15 M NaCl, pH 7.2) the IgG was eluted with 0.58% vol/vol acetic acid in 0.9% wt/vol NaCl. The eluate was dialyzed and concentrated by ultrafiltration into phosphate-buffered saline and then dialyzed into barbitalbuffered saline. Approximately 43% of the inhibitory activity in Bethesda units and 35 mg of IgG were recovered. A 1.0-ml immunoadsorbent was prepared by coupling the Thr35t-Ser365 peptide to cyanogen bromide-activated Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) according to manufacturer's instructions at a density of 2 Mmol/ml of swollen gel. The purified IgG (6.7 mg) was mixed batchwise with the gel overnight (16-18 h ) at room temperature. After washing with barbital-buffered saline, the bound IgG was eluted with 0.05 M diethylamine in barbital-buffered saline (pH 11). The eluate was immediately neutralized with monobasic sodium phosphate, made 0.01% in bovine serum albumin, and concentrated and dialyzed into barbital-buffered saline by centrifugal ultrafiltration. The enriched FVIII inhibitor preparation was diluted to produce a preparation of approximately equivalent FVIII inhibitory activity as that ofthe inhibitor plasma in a 1:9 dilution. The enriched FVIII inhibitor was then preincubated with synthetic FVIII peptide and assayed as described above.
FVIII ELISA. In this system, purified human FVIII was diluted to -3 U/ml in 20 mM Tris-HCl, 0.02% NaN3, pH 9.6, and 100 Ml added to each 1.0 X 0.6-cm well of a multiwell tissue culture plate (Linbro, Flow Laboratories Inc., McLean, VA) and incubated at room temperature for 2 h. The plates were then stored in this solution at 4VC until use. Prior to use, the solution was removed and the wells were blocked with 200 Ml of 20 mM Tris-HCl, 0.02% NaN3, 1% bovine serum albumin for 1 h at room temperature. After blocking, the solution was removed and the wells were washed three times with 250 Ml of a buffer containing 0.14 M NaCi, 0.0015 M KH2PO4, 0.0084 M Na2HPO4, 0.05% Nonidet P-40 (washing buffer). Alternatively, purified FVIII was diluted in 0.01 M NaHCO3 and 100 ul was added to each well. The plates were then desiccated at room temperature, and stored at 4VC until use. Prior to use, the wells were blocked and washed as described above. 100 ,l of sample solution containing monoclonal antibody C5 and synthetic FVIII peptide was then added to each well. C5 at a final concentration of 0.4-1 Mg/ml, and FVIII peptide at a final concentration of 1 gM to 1 mM in washing buffer with 1% bovine serum albumin, were preincubated for 2 h at 37°C or overnight (16) (17) (18) (27) block the binding of C5 to FVIII adsorbed to the surface of microtiter wells in an ELISA system. Synthetic peptides based on the amino acid sequence of FVIII light chain were used as control peptides. Fig. 2 depicts the amino acid sequence of amino acid residues 330-376 of the heavy chain of FVIII, the activated protein C cleavage site at Arg336, and the thrombin cleavage site at Arg372 (7). The amino acid sequence of the synthetic peptides used in these studies is also depicted in this figure.
In the ELISA system, the synthetic FVIII peptide Thr35'-Ser365 demonstrated dose-dependent inhibition of C5 binding to FVIII with -50% of maximal inhibitory activity at a concentration of 0.75 AM and near total inhibition at a concentration of 100 gM (Fig. 3) . Two other peptides, Asn340-Glu354
and Glu342-Asp356, demonstrated partial inhibition of C5 binding but at an -100-fold greater concentration than that required for Thr"'-Ser365 (Fig. 3) . The amino acid sequences of these three peptides partially overlap and have in common the amino acid residues 351-354 (Fig. 2) . Since all three peptides have some reactivity with C5, then the C5-binding region must involve one or more amino acid residues in the common sequence. However, given the marked difference in concentration requirements to demonstrate reactivity, the C5-binding region must also involve additional amino acid residues between residue numbers 357 and 365, which are not contained in the overlap. Light chain control peptides Arg'645-Gln'659 and Val'670-Glu'684 failed to demonstrate any inhibition of C5 binding at concentrations up to 1 mM (Fig. 3) .
Since C5 demonstrated inhibition of FVIII procoagulant activity in plasma, the individual synthetic FVIII peptides were tested for the ability to neutralize this effect of C5. Fig. 4 demonstrates that the Thr351-Ser365 peptide was able to neu- 330  340  350  360 tralize C5-induced prolongation of the APTT in a dose-dependent manner with near total neutralization at a final concentration of 3 mM. Partially overlapping peptides Asn340-GlU354, Val357_I-e371, and Glu342-Asp356 had no effect on the prolongation of the APTT by C5 at concentrations up to 4-5 mM (Fig. 4) . Likewise, light chain control peptides Glu'66-Lys1674 and Arg178'-Asp'795 had no effect (data not shown). Data are plotted as the number of seconds the APTT is prolonged over a control assay containing no synthetic FVIII peptide. Synthetic FVIII peptide alone had no effect on the APTT.
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Discussion
The results presented here clearly demonstrate that the binding region of the FVIII-inhibiting monoclonal antibody C5 and a human FVIII inhibitor alloantibody resides between amino acid residues Thri5l-Ser365. The (31) . In addition, the immunoblot reactivity of C5 with a bacterially produced FVIII fragment containing amino acid residues 326-740 also localized the epitope to residues 326-372 (unpublished observations). The synthetic FVIII peptide method not only allows further restriction of the binding site, but also assures specificity by demonstrating blocking of the FVIII inhibitory activity of C5 in fluid phase.
Localization of the C5-binding region to amino acid residues Thr35'-Ser365, which lies between two critical cleavage sites in the FVIII heavy chain, suggests that it is at, or near, structures important to the modulation of FVIII procoagulant activity. As proposed by Eaton et al. (7), thrombin cleavage of the 92-kD heavy chain at Arg372 produces 54-and 44-kD subunit peptides and results in FVIII procoagulant activity (Fig.  1) . Cleavage of the 54-kD peptide at Arg336 by activated protein C or factor Xa results in production of a 45-kD cleavage peptide and loss of FVIII procoagulant activity (7) (Fig. 1) .
They suggested that the region between these two cleavage sites may be functionally important in regulating FVIII procoagulant activity. The description of a binding epitope of a FVIII inhibitory antibody to this region supports this supposition. It is further supported by the finding that this peptide segment also partially neutralizes a human FVIII inhibitor alloantibody.
The FVIII inhibitory activity of the human alloantibody tested was only partially neutralized by preincubation with the Thr35'-Ser365 peptide at concentrations up to 5 mM. This is consistent with the observation that the antibody is oligoclonal in nature and has reactivity with both the 54-and 44-kD thrombin generated fragments of FVIII heavy chain (30) . Partial purification of the FVIII inhibitor by protein A chromatography followed by immunoaffinity chromatography with the Thr"'-Ser365 peptide coupled to Sepharose appears to have resulted in the recovery of a population of FVIII inhibitor which was more completely neutralized by the Thr351-Ser365 peptide. Incubation of the inhibitor plasma with 2.5 mM Thr3"-Ser365 resulted in a 46% reduction in the APTT prolongation produced by the inhibitor plasma. No further reduction was noted with incubation at a concentration of 5 mM peptide. Incubation ofa preparation ofpartially purified inhibitor (containing the same Bethesda unit activity as the inhibitor plasma) with 5 mM peptide resulted, however, in a 80% reduction ofthe APTT prolongation. Some ofthe FVIII inhibitory activity of this patient's plasma may result from alloantibodies reactive with the 44-kD FVIII heavy chain fragment. FVIII inhibitory alloantibodies with reactivity only to the 44-kDa fragment have been described (30) .
The region that contains the C5-binding area, is an unusually acidic region ofthe protein. This acidic region (amino acid residues 331-372) contains 15 aspartic and glutamic acid residues with only four lysine or arginine residues out of42 amino acids (4, 7, 1 1) (Fig. 2) . The region also functions as a spacer region between the first (amino acid residues 1-328) and second (amino acid residues 380-71 1) A domains (1 1). An analogous acidic region occurs in the light chain (amino acid residues 1649-1689) which also contains 15 aspartic and glutamic acid residues and only four lysine or arginine residues out of41 amino acids (4, 7, 1 1). This latter acidic region also preceeds a critical thrombin cleavage site at Arg'689 necessary for activation of FVIII (4, 16) . These two acidic regions also contain some amino acid residue sequence homology (32, 33) . The control peptides used in this study contained amino acid sequences from the acidic region ofthe light chain. It is therefore unlikely that the results obtained here were simply a result of the acidic nature of the peptides. It is of interest that the binding region of a FVIII-inhibiting anti-FVIII peptide antibody has been localized to a seven-amino acid segment of the acidic region of the light chain (23).
The actual mechanism ofthe inhibition ofFVIII procoagulant activity by C5 or the alloantibody inhibitor is not known. The binding of these antibodies may inhibit FVIII activation by interfering with the thrombin cleavage at Arg372 (Fig. 1 ).
This mechanism of inhibition has been postulated as the cause of FVIII inactivation by a FVIII inhibitor (34) . Binding of these antibodies could sterically block the thrombin cleavage site, or render it inaccessible through the induction of conformational changes in the FVIII molecule. It is also possible that their binding has no effect on thrombin cleavage, but prevents the effective interaction or binding of FVIII with other constituents of the coagulation mechanism such as factor IXa, factor X, calcium ions, or phospholipid.
There is evidence that the acidic regions of FVIII may be involved in protein-protein interactions. A monoclonal anti-FVIII antibody, whose binding region is contained within the acidic region of the light chain of FVIII, has been reported to block the binding of FVIII to von Willebrand factor (35 
